In vitro neutralization studies confirm lessened Moderna vaccine effectiveness against COVID-19 mutations

In a manuscript posted to a preprint server, Moderna Inc. addressed Monday the results of in vitro neutralization studies of sera from people vaccinated against emerging strains of SARS-CoV-2, which produced lesser, though still protective, results.

Specifically, the variants being fretted over are those identified first in the U.K. and the Republic of South Africa, B.1.1.7 and B.1.351. The former has proven to be more effective at infection, while the latter has worried health experts with its potential to diminish vaccine efficacy.

To an extent, that fear was realized in the study, which showed a six-fold reduction in neutralizing titers, though Moderna cautioned that this means its vaccine is still effective, just less so. However, for the U.K. variant, the vaccine was just as effective as ever. The results have spurred Moderna to test an additional booster dose of its COVID-19 vaccine to study the ability to boost efficacy against emerging strains. Normally, the vaccine consists of a two-dose regimen.

Going forward, the company is creating an emerging variant booster candidate targeted at the South African variant specifically. That candidate has gone into preclinical studies and a phase one study in the United States to evaluate any benefits it may provide.

“As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves,” Moderna CEO Stéphane Bancel said. “We are encouraged by these new data, which reinforce our confidence that the Moderna COVID-19 Vaccine should be protective against these newly detected variants. Out of an abundance of caution and leveraging the flexibility of our mRNA platform, we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic to determine if it will be more effective to boost titers against this and potentially future variants.”

This study was conducted in collaboration with the Vaccine Research Center, a part of the National Institute of Allergy and Infectious Diseases (NIAID). Its results will be submitted for peer-reviewed publication at a later date.

Chris Galford

Recent Posts

Curtiss-Wright secures Army Enduring Shield platform support contract

The U.S. Army has awarded engineering solutions firm Curtiss-Wright Corporation a contract supporting the new…

2 days ago

GAO, Rep. Clarke call for greater implementation of federal cybersecurity efforts

Although the majority – nearly 79 percent – of recommendations related to federal cybersecurity called…

2 days ago

Air Force to conduct next BRAVO hackathon in March to develop prototypes

The United States Department of the Air Force will conduct a BRAVO hackathon from March…

2 days ago

Legislation seeks to enable ATF to electronically search gun sale records

U.S. Sen. Dianne Feinstein (D-CA) and U.S. Rep. Bill Pascrell (D-NJ) recently introduced the Crime…

2 days ago

DHS to implement victim-centered approach into policies for human trafficking

According to the second annual report from the Center for Countering Human Trafficking (CCHT), a…

3 days ago

Bipartisan Senate push yields Wildfire Emergency Act to address western wildfires

Seeking to increase preparedness for wildfires and reduce the risks they pose, a bipartisan group…

3 days ago

This website uses cookies.